Empowering a Multidisciplinary Community to Facilitate Timely Diagnosis and Treatment of Thyroid Eye Disease - Final Assessment

In this last course of the series, we’ll use a ‘test-and-teach’ approach to determine how your knowledge of TED has changed from having participated in this series]
1.
Recognize the prevalence and risk factors for TED.
2.
Describe the clinical signs and symptoms, grading system, and tests/imaging used to diagnose TED.
3.
Review the differential diagnosis for TED.
4.
Evaluate clinical and real-world data investigating the use of biologics in patients with TED.
5.
Implement educational practices that improve patient knowledge of TED diagnosis, management, and treatment.
6.
Develop effective co-management strategies to improve outcomes for patients with TED.

This activity is supported by an unrestricted educational grant from Horizon Therapeutics.

In the first course of the series, we’ll use a ‘test-and-teach’ approach to establish your base knowledge of thyroid eye disease (TED)

Target Audience
This certified continuing education activity is designed for primary care providers, endocrinologists, comprehensive ophthalmologists, optometrists, oculoplastic surgeons, and  neuro-ophthalmologists involved in the care of patients with thyroid eye disease (TED).

LEARNING OBJECTIVES
Upon completion of this activity, the participant should be able to:

  • Recognize the prevalence and risk factors for TED
  • Describe the clinical signs and symptoms, grading system, and tests/imaging used to diagnose TED
  • Review the differential diagnosis for TED
  • Evaluate clinical and real-world data investigating the use of biologics in patients with TED
  • Implement educational practices that improve patient knowledge of TED diagnosis, management, and treatment
  • Develop effective comanagement strategies to improve outcomes for patients with TED

ACCREDITATION STATEMENT
Provided by Evolve Medical Education, LLC (Evolve)



Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians
Evolve designates this Other activity (Gather-Ed curriculum) for a maximum of 4.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistant Continuing Education
PAs may claim a maximum of 4.5 Category 1 credits for completing this activity. National Commission on Certification of Physician Assistants (NCCPA) accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

DISCLOSURE POLICY 
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

The following faculty/staff members have the following financial relationships with ineligible companies.

Jennifer Murdock, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alastin Skincare, Inc., Galderma Laboratories, L.P., and Horizon Therapeutics. Speaker's Bureau: Horizon Therapeutics.

Andrea Kossler, MD, FACS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Acelyrin, Argenx, Genentech, Horizon Therapeutics, Immunovant, and Kriya Therapeutics. Grant/Research Support: Horizon Therapeutics, Kriya Therapeutics, Sling, and Viridian.

The Evolve staff, planners, and reviewer have no financial relationships with ineligible companies.

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER 
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Horizon Therapeutics.

This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.